Vallerie McLaughlin
Kim A Eagle M.D. Endowed Professor of Cardiovascular Medicine
Associate Chief Clinical Officer and Professor of Internal Medicine
Cardiovascular Medicine
1500 E. Medical Center Drive, SPC 5853
Ann Arbor, Michigan 48109-5853
[email protected]

Available to mentor
Vallerie McLaughlin
Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • Qualifications
    • MD
      Northwestern University Medical School, Evanston, 1989
    • BS
      Northwestern University, Evanston, 1985
    Center Memberships
    • Center Member
      Samuel and Jean Frankel Cardiovascular Center
    Research Overview

    1. Pulmonary Hypertension
    2. Pulmonary vascular disease

    Recent Publications See All Publications
    • Journal Article
      Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
      Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry J-L, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey J-M, Elman E, Tompkins C-A, Parsley E, Aranda R, Zisman LS, Ghofrani H-A, TORREY Study Investigators . Lancet Respir Med, 2024 Jul; 12 (7): 523 - 534. DOI:10.1016/S2213-2600(24)00072-9
      PMID: 38705167
    • Journal Article
      Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease.
      Ilonze OJ, Ebong IA, Guglin M, Nair A, Rich J, McLaughlin V, Tedford RJ, Mazimba S. JACC Heart Fail, 2024 Jun 24; DOI:10.1016/j.jchf.2024.04.031
      PMID: 38970588
    • Journal Article
      Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.
      Channick R, Chin KM, McLaughlin VV, Lammi MR, Zamanian RT, Turricchia S, Ong R, Mitchell L, Kim NH. Cardiol Ther, 2024 Jun; 13 (2): 315 - 339. DOI:10.1007/s40119-024-00361-w
      PMID: 38451426
    • Proceeding / Abstract / Poster
      Baseline Characteristics From the IMPAHCT Trial of AV-101, Inhaled Imatinib, in Subjects With Pulmonary Arterial Hypertension
      Gillies H, Chakinala MM, Dake B, Feldman JP, Hoeper M, Humbert MJC, Jing Z-C, Langley J, Mclaughlin VV, Niven R, Rosenkranz S, Zhang X, Hill NS. 2024 May; a6096 - a6096. DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6096
    • Proceeding / Abstract / Poster
      Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates With Hemodynamics and Is Consistent With REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
      Lachant DJ, Osterhout R, Chakinala MM, Franco V, Mcconnell JW, Rahaghi FF, Sahay S, Sood N, Spikes LA, Benza RL, Channick RN, Chin KM, Frantz RP, Ghofrani HA, Hemnes AR, Howard LS, Mclaughlin VV, Sitbon O, Zamanian RT, Roscigno RF, Mottola D, Parsley E, Cravets M, Bruey J-M, Zisman LS, White RJ. 2024 May; a7475 - a7475. DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7475
    • Proceeding / Abstract / Poster
      Impact of Delaying Access to Sotatercept on Patients Living With Pulmonary Arterial Hypertension
      Mclaughlin VV, Alsumali A, Lui R, Martinez EC, Nourhussein I, Klok R, David B, Chevure J, de Oliveira Pena J, Lautsch D, Hoeper M. 2024 May; a5429 - a5429. DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5429
    • Proceeding / Abstract / Poster
      Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
      Sitbon O, Sahay S, Escribano Subías P, Zolty RL, Kingrey JF, Penn B, Sobol I, Sood N, Benza RL, Channick RN, Chin KM, Frantz RP, Hemnes AR, Howard LS, Mclaughlin VV, Vachiéry J-L, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Parsley E, Aranda R, Zisman LS, Ghofrani H-A, on behalf of the TORREY Study Investigators . 2024 May; a1011 - a1011. DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011
    • Journal Article
      Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
      Distler O, Bonderman D, Coghlan JG, Denton CP, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Vonk MC, Di Scala L, Lemarie J-C, Perchenet L, Hachulla É. Arthritis Rheumatol, 2024 May; 76 (5): 777 - 782. DOI:10.1002/art.42791
      PMID: 38146100